ALX Oncology Secures Up to $50M Debt Facility from HSBC Ventures, Refinances Existing Loans
ALXO has more than doubled off its 52-week low of $0.404 on elevated volume (9.8× avg).
Summary
ALX Oncology secured a new multi-tranche term loan facility of up to $50 million from HSBC Ventures, simultaneously refinancing its prior debt. The company drew $10 million at closing, with an additional $20 million available through June 2028 and further tranches tied to clinical milestones. This financing significantly extends ALXO's liquidity and financial runway, with the new loans maturing in 2030. This news follows the 8-K filed at the same time, detailing the new financing.
At the time of this announcement, ALXO was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $274.5M. The 52-week trading range was $0.40 to $2.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.